Warning: count(): Parameter must be an array or an object that implements Countable in /home/medteche/public_html/wp-content/themes/medtech-engine/header.php on line 133

Innovation & Entrepreneurship

Innovation & Entrepreneurship

Watch me bleed: why women should be (very) angry about the lack of gender-specific health solutions


Is medical research still hampered by the delusion that women are an inferior byproduct of men? It sounds far-fetched but Ava co-founder and CEO, Lea von Bidder, believes the lack of health solutions for female-specific conditions might well be down to outmoded ‘spare rib’ views and an inability to talk about menstrual issues frankly


Earlier this year, 31-year-old actress and writer Lena Dunham shared her decision to undergo a hysterectomy to end her long, painful struggle with endometriosis. She explained how terminating her fertility was worth the benefit of alleviating the pain and suffering she had been experiencing for years as a result of her condition.

Dunham’s decision was met with dismissive ‘think pieces’. Experts who had no background about her medical history pronounced her decision flawed, as if it were the flippant choice of a hapless millennial, not a self-assured young woman who was simply tired of suffering and had run out of other options. But the really interesting question here isn’t about analysing a famous young woman’s ‘extreme’ life choices, rather, it’s why medical research has failed to deliver better solutions to women who are suffering.

The answer has to do with a dirty secret of medical research – a lot of the stuff we think we know about humans, we actually only know about men. Why? Because medicine still sees the female body as an unruly variant of the male base model, an obstacle rather than an opportunity.

For years, researchers have been reluctant to include women as clinical trial subjects, claiming that cyclical fluctuations in oestrogen and progesterone added too much variability to data sets. It’s not rocket science to run the statistical analysis and include enough women in the subject pool so that hormone phase can be used as a statistical factor. Even when studies do include males and females, many do not statistically analyse sex or cycle phase as a factor. This means that valuable information about whether a drug or its side effects is more impactful in males or females is lost. But researchers too often adopt the blunt approach of defaulting to male subjects and assuming their findings will be relevant for female physiology.

Lea von Bidder

The irony, of course, is that drugs that were not sufficiently tested on women (because of concern about how women’s bodies might react) may then go on to harm women. The most famous example of this is the insomnia drug Ambien. Once on the market, Ambien was prescribed to men and women at equal doses. However only after the drug was being widely prescribed and women were suffering did the problem become clear – Ambien takes a longer time to clear from the system of women than men, dangerously increasing the risk for overdose and adverse side effects for women.

When research in this area does occur, too often it’s about trivial socio-sexual differences which are then sensationalised by the media, like what types of men women find most attractive during their fertile window (shocker: a meta-analysis of over 50 studies found no significant link between menstrual cycle and partner preference qualities) or whether strippers receive more tips when they’re ovulating (a study which everyone seems to have heard of, even though it only looked at 18 subjects for only two months).

A case of extremes

We have major blind spot in medical research: we either pretend that women’s bodies are the same as men or treat their differences as trivialities to share in the pages of Cosmo magazine. These two extremes – ignoring physiological differences between the sexes or only focusing on them in the most superficial ways – miss the obvious ideal middle ground, acknowledging that the menstrual cycle is a basic physiological phenomenon affecting half the population at some point in their lives and taking it into account when doing medical research.

Why design more than matters in medtech – KOLs discuss the future

In this next article, McKinsey & Co’s Thomas Nilsson and Benedict Sheppard speak with three leaders about how the discipline is improving medical products and driving innovation.


A stunning lack of appreciation for female physiology has slowed progress in women’s health research. We’re behind where we should be in understanding how the menstrual cycle impacts overall health, and how cyclical hormonal changes impact conditions like asthma and migraines and are even related to the risk of developing serious conditions like Alzheimer’s and heart disease. We still routinely prescribe women powerful medications – like sleeping pills and anti-depressants – without understanding the impact they will have on female physiology. And we’re still leaving women like Lena Dunham with too few options for dealing with her chronic menstrual pain, leading to her taking the extreme measure of having a hysterectomy at such a young age.

So what can we do? We can toss out the broken record player and upgrade how we talk about the cycle to break down the menstrual stigma. We need to challenge it culturally – meaning the way we talk about it in conversation, as well as in medical research – meaning we need research to study the cycle, in relation to reproductive and general health.

Medical research should aim for equality, but equality is more complex than equal numbers of male and female subjects in experiments. Women are biologically different from men, and equality in research means using those differences as opportunities to understand men’s health and women’s health so that both genders equally benefit from medical research.

For more on women’s health, click here.

About the author

Journalist and editor Kathryn Reilly has worked in consumer, contract and medical writing for more than 20 years.

Expert Insight

The European public-procurement opportunity: delivering value in medtech

The magic of innovation: Interview with Billy Cohn, MD

The MedTech Roadmap: a medical device’s journey from concept to market

An introduction to Beth Susanne – international pitch coach

Be first to know

Key resources


You're the expert! Write for The Engine or share your articles, papers and research

Add your content

Add your content

Keep informed

Sign up for Ignition, our regular, ideas-packed newsletter

Sign in with social media

or with a username